ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1515686
Adherence, Satisfaction, and Quality of Life in Wilson Disease Patients After Switching to Trientine Tetrahydrochloride: Observational Data from a Dual Cohort Study
Provisionally accepted
Valentina Medici1
Nora Cazzagon2*
Pier Maria Battezzati3Andrea Crosignani3
Alberto Civolani4Emanuela Bonaiuto2
Renata D'Incà2
Emanuela Vargiu4
Fabio Tedone5
Stefania Lopatriello5Massimo Zuin6*- 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, University of California, Davis, Davis, California, United States
- 2Department of Surgery, Oncology and Gastroenterology, University of Padova; RARE-LIVER ERN, Azienda Ospedale – Università Padova, Padova, Italy
- 3Department of Health Sciences, University of Milan ; ASST Santi Paolo e Carlo, RARE-LIVER ERN, Polo universitario San Paolo, Milano, Italy
- 4UOC Gastroenterology AOU Cagliari Policlinico “Duilio Casula”, Cagliari, Italy
- 5Helaglobe, Firenze, Italy
- 6Department of Health Sciences, University of Milan, Milano, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Word count: 172 The study focuses on Wilson disease, a liver disorder involving copper accumulation due to defective hepatic copper transport. The manuscript's emphasis on improving treatment adherence and quality of life in patients with this hepatobiliary condition fits the journal's interest in advancing the understanding and management of liver diseases, particularly in areas such as chronic hepatic conditions and drug-induced outcomes. The manuscript addresses the challenges of lifelong treatment adherence in WD, explores novel therapeutic outcomes, and contributes to the management of hepatobiliary diseases, which is central to the journal's mission. Furthermore, the study connects basic research with clinical applications, aligning with the journal's goal of advancing diagnosis and treatment in hepatobiliary conditions.VM serves in the advisory board for Orphalan, Alexion Pharmaceuticals, and Arbormed; received research grants from Arbormed; site PI for Orphalan, Vivet Therapeutix and Ultragenix clinical trials. NC: has participated in advisory board for IPSEN and Albireo; received speaking fees from Orphalan, Intercept, Advanz; received travel grants from Orphalan; site PI for IPSEN, GSK, Falk pharma, Calliditas pharmaceuticals, Cymabay. PMB declares collaboration
Keywords: Wilson disease, Trientine tetrahydrochloride, Copper, patient-reported outcomes, Treatment Adherence, Quality of life (QoL)
Received: 07 Nov 2024; Accepted: 30 Aug 2025.
Copyright: © 2025 Medici, Cazzagon, Battezzati, Crosignani, Civolani, Bonaiuto, D'Incà, Vargiu, Tedone, Lopatriello and Zuin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Nora Cazzagon, Department of Surgery, Oncology and Gastroenterology, University of Padova; RARE-LIVER ERN, Azienda Ospedale – Università Padova, Padova, Italy
Massimo Zuin, Department of Health Sciences, University of Milan, Milano, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.